Thilo Schroeder - Feb 18, 2020 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
Director
Signature
/s/ Darren DeStefano, Attorney-in-Fact
Stock symbol
RVMD
Transactions as of
Feb 18, 2020
Transactions value $
$28,615,233
Form type
4
Date filed
3/4/2022, 06:22 PM
Previous filing
Mar 4, 2022
Next filing
May 7, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Conversion of derivative security +2.12M 2.12M Feb 18, 2020 By Nextech V Oncology S.C.S., SICAV-SIF F1, F2
transaction RVMD Common Stock Purchase $6.8M +400K +18.88% $17.00 2.52M Feb 18, 2020 By Nextech V Oncology S.C.S., SICAV-SIF F2
transaction RVMD Common Stock Purchase $3.9M +150K +5.96% $26.00 2.67M Jul 13, 2020 By Nextech V Oncology S.C.S., SICAV-SIF F2
transaction RVMD Common Stock Purchase $13.5M +300K $45.00 300K Feb 8, 2021 By Nextech VI Oncology SCSp F3
transaction RVMD Common Stock Purchase $2.2M +116K $18.94 116K Mar 2, 2022 By Nextech Crossover I SCSP F4, F5
transaction RVMD Common Stock Purchase $1.01M +54.8K +47.09% $18.42 171K Mar 3, 2022 By Nextech Crossover I SCSP F5, F6
transaction RVMD Common Stock Purchase $208K +10.9K +6.36% $19.13 182K Mar 3, 2022 By Nextech Crossover I SCSP F5, F7
transaction RVMD Common Stock Purchase $996K +56.3K +30.95% $17.69 238K Mar 4, 2022 By Nextech Crossover I SCSP F5, F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Series B Preferred Stock Conversion of derivative security -1.57M -100% 0 Feb 18, 2020 Common Stock 1.57M By Nextech V Oncology S.C.S., SICAV-SIF F1, F2
transaction RVMD Series C Preferred Stock Conversion of derivative security -549K -100% 0 Feb 18, 2020 Common Stock 549K By Nextech V Oncology S.C.S., SICAV-SIF F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of the Issuer's common stock upon the closing of the Issuer's initial public offering.
F2 Nextech Invest AG is the investment advisor of Nextech V Oncology S.C.S., SICAV-SIF ("Nextech V"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech V. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F3 Nextech Invest AG is the investment advisor of Nextech VI Oncology SCSp ("Nextech VI"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech VI. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F4 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.62 to $19.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F5 Nextech Invest AG is the investment advisor of Nextech Crossover I SCSP ("Nextech Crossover"). The reporting person is a managing member at Nextech Invest AG and may therefore be deemed to be the beneficial owner of shares held by Nextech Crossover. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F6 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.03 to $18.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.05 to $19.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F8 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.25 to $18.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.